دورية أكاديمية
أعرض في EDS

Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies.

التفاصيل البيبلوغرافية
العنوان: Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies.
المؤلفون: Wang M; Department of Ophthalmology, Changxing County People's Hospital, 66 Taihu Middle Road, Zhicheng Town, Changxing County, Huzhou city, Zhejiang Province, China., Lu J; Department of Ophthalmology, Changxing County People's Hospital, 66 Taihu Middle Road, Zhicheng Town, Changxing County, Huzhou city, Zhejiang Province, China., Dong J; Department of Ophthalmology, Changxing County People's Hospital, 66 Taihu Middle Road, Zhicheng Town, Changxing County, Huzhou city, Zhejiang Province, China. 15857288244@163.com.
المصدر: BMC ophthalmology [BMC Ophthalmol] 2024 Jun 28; Vol. 24 (1), pp. 272. Date of Electronic Publication: 2024 Jun 28.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967802 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2415 (Electronic) Linking ISSN: 14712415 NLM ISO Abbreviation: BMC Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Diabetic Retinopathy*/drug therapy , Dipeptidyl-Peptidase IV Inhibitors*/adverse effects , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use, Humans ; Incidence ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications ; Risk Factors ; Disease Progression
مستخلص: Background: The purpose of this review was to examine if dipeptidyl peptidase-4 inhibitor (DPP4i) use affects the risk of diabetic retinopathy (DR).
Methods: Cohort studies published up to 20th July 2023 in the databases of PubMed, CENTRAL, Embase, Scopus, and Web of Science were searched. The adjusted effect size was pooled to calculate the odds ratio (OR).
Results: Seven studies were included. Meta-analysis showed that the use of DPP4i was not associated with any significant change in the risk of DR (OR: 0.86 95% CI: 0.70, 1.06 I 2  = 78%). The pooled analysis also found that DPP4i use was not associated with any significant risk of progression of DR (OR: 0.87 95% CI: 0.47, 1.59 I 2  = 86%). The results did not change during sensitivity analysis.
Conclusion: Present evidence from a limited number of real-world studies shows that DPP4i may not affect the incidence and progression of DR. There is a need for further studies from different countries using accurate definitions of DR and its progression to validate the current results.
(© 2024. The Author(s).)
References: BMJ. 2011 Nov 24;343:d6898. (PMID: 22115901)
Sci Rep. 2016 Jul 06;6:29393. (PMID: 27381080)
Heart Vessels. 2023 Nov;38(11):1371-1379. (PMID: 37522902)
Retina. 2016 Dec;36(12):2357-2363. (PMID: 27285457)
J Diabetes Res. 2020 May 25;2020:2450781. (PMID: 32566677)
J Diabetes Investig. 2021 Aug;12(8):1322-1325. (PMID: 33316144)
Diabetes Obes Metab. 2018 May;20(5):1262-1279. (PMID: 29369494)
Clin Exp Ophthalmol. 2016 May;44(4):260-77. (PMID: 26716602)
Diabetes Metab J. 2019 Oct;43(5):640-648. (PMID: 30877707)
Molecules. 2022 May 10;27(10):. (PMID: 35630534)
Curr Drug Saf. 2023;19(2):236-243. (PMID: 37078347)
J Diabetes Investig. 2019 May;10(3):745-752. (PMID: 30300472)
J Clin Med. 2021 Jun 28;10(13):. (PMID: 34203446)
Cardiovasc Diabetol. 2021 Apr 28;20(1):91. (PMID: 33910574)
Biomed Pharmacother. 2018 Jun;102:833-838. (PMID: 29605771)
JAMA. 2019 Jan 1;321(1):69-79. (PMID: 30418475)
Handb Exp Pharmacol. 2022;274:415-438. (PMID: 35112236)
Diabetes Care. 2012 Mar;35(3):556-64. (PMID: 22301125)
Curr Ther Res Clin Exp. 2020 Jul 25;93:100596. (PMID: 32817765)
Diabetes Care. 2020 Nov;43(11):2859-2869. (PMID: 32938746)
Diabetes Ther. 2016 Sep;7(3):483-96. (PMID: 27262995)
Diabetes Metab. 2018 Sep;44(4):361-367. (PMID: 29752167)
Int J Surg. 2021 Apr;88:105906. (PMID: 33789826)
N Engl J Med. 2015 Jul 16;373(3):232-42. (PMID: 26052984)
Diabetes Care. 2018 Sep;41(9):1998-2009. (PMID: 30012674)
Expert Rev Clin Pharmacol. 2022 Jul;15(7):877-886. (PMID: 35839519)
Nat Rev Dis Primers. 2016 Mar 17;2:16012. (PMID: 27159554)
Cardiovasc Diabetol. 2014 Jan 14;13:19. (PMID: 24423149)
Diabetologia. 2018 Nov;61(11):2412-2421. (PMID: 30097694)
Clin Med Insights Cardiol. 2020 Sep 2;14:1179546820953410. (PMID: 32952404)
Diabetes Obes Metab. 2012 May;14(5):454-63. (PMID: 22151893)
Nat Rev Endocrinol. 2020 Nov;16(11):642-653. (PMID: 32929230)
فهرسة مساهمة: Keywords: DPP4; Eye; Medications; Microvascular complications; Oral hypoglycemics; Retinopathy
المشرفين على المادة: 0 (Dipeptidyl-Peptidase IV Inhibitors)
تواريخ الأحداث: Date Created: 20240629 Date Completed: 20240629 Latest Revision: 20240701
رمز التحديث: 20240701
مُعرف محوري في PubMed: PMC11212248
DOI: 10.1186/s12886-024-03535-1
PMID: 38943083
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2415
DOI:10.1186/s12886-024-03535-1